Articles with public access mandates - Terzah HortonLearn more
Available somewhere: 62
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia
KL Bride, TL Vincent, SY Im, R Aplenc, DM Barrett, WL Carroll, R Carson, ...
Blood, The Journal of the American Society of Hematology 131 (9), 995-999, 2018
Mandates: US National Institutes of Health
JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias
C Delgado-Martin, LK Meyer, BJ Huang, KA Shimano, MS Zinter, ...
Leukemia 31 (12), 2568-2576, 2017
Mandates: US National Institutes of Health
Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group
R Aplenc, S Meshinchi, L Sung, T Alonzo, J Choi, B Fisher, R Gerbing, ...
Haematologica 105 (7), 1879, 2020
Mandates: US National Institutes of Health
Poly (ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O 6-methylguanine …
TM Horton, G Jenkins, D Pati, L Zhang, ME Dolan, A Ribes-Zamora, ...
Molecular cancer therapeutics 8 (8), 2232-2242, 2009
Mandates: US National Institutes of Health
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4
CR Cruz, U Gerdemann, AM Leen, JA Shafer, S Ku, B Tzou, TM Horton, ...
Clinical Cancer Research 17 (22), 7058-7066, 2011
Mandates: US National Institutes of Health
Bortezomib reinduction chemotherapy in high‐risk ALL in first relapse: a report from the Children's Oncology Group
TM Horton, JA Whitlock, X Lu, MM O'Brien, MJ Borowitz, M Devidas, ...
British journal of haematology 186 (2), 274-285, 2019
Mandates: US National Institutes of Health
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre …
PD Cole, KM McCarten, Q Pei, M Spira, ML Metzger, RA Drachtman, ...
The Lancet Oncology 19 (9), 1229-1238, 2018
Mandates: US National Institutes of Health
A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916)
JA Muscal, PA Thompson, TM Horton, AM Ingle, CH Ahern, RM McGovern, ...
Pediatric blood & cancer 60 (3), 390-395, 2013
Mandates: US National Institutes of Health
Children's Oncology Group Trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma
DT Teachey, M Devidas, BL Wood, Z Chen, RJ Hayashi, ML Hermiston, ...
Journal of Clinical Oncology 40 (19), 2106-2118, 2022
Mandates: US National Institutes of Health
Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors
D Niewerth, NE Franke, G Jansen, YG Assaraf, J van Meerloo, CJ Kirk, ...
Haematologica 98 (12), 1896, 2013
Mandates: Netherlands Organisation for Health Research and Development, Royal …
A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study
TR Hummel, L Wagner, C Ahern, M Fouladi, JM Reid, RM McGovern, ...
Pediatric blood & cancer 60 (9), 1452-1457, 2013
Mandates: US National Institutes of Health
Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin’s lymphoma
SM Castellino, Q Pei, SK Parsons, D Hodgson, K McCarten, T Horton, ...
New England Journal of Medicine 387 (18), 1649-1660, 2022
Mandates: US National Institutes of Health
Severe neurologic side effects in patients being treated for hemophagocytic lymphohistiocytosis
PA Thompson, CE Allen, T Horton, JY Jones, AA Vinks, KL McClain
Pediatric blood & cancer 52 (5), 621-625, 2009
Mandates: US National Institutes of Health
A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a …
TM Horton, JP Perentesis, AS Gamis, TA Alonzo, RB Gerbing, J Ballard, ...
Pediatric blood & cancer 61 (10), 1754-1760, 2014
Mandates: US National Institutes of Health
Endogenous knockdown of survivin improves chemotherapeutic response in ALL models
DJ Morrison, LE Hogan, G Condos, T Bhatla, N Germino, NP Moskowitz, ...
Leukemia 26 (2), 271-279, 2012
Mandates: US National Institutes of Health
Accuracy of adverse event ascertainment in clinical trials for pediatric acute myeloid leukemia
TP Miller, Y Li, M Kavcic, AB Troxel, YSV Huang, L Sung, TA Alonzo, ...
Journal of Clinical Oncology 34 (13), 1537-1543, 2016
Mandates: US National Institutes of Health
Transmissible ER stress reconfigures the AML bone marrow compartment
B Doron, S Abdelhamed, JT Butler, SK Hashmi, TM Horton, P Kurre
Leukemia 33 (4), 918-930, 2019
Mandates: US National Institutes of Health
Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes
LK Meyer, BJ Huang, C Delgado-Martin, RP Roy, A Hechmer, ...
The Journal of clinical investigation 130 (2), 863-876, 2020
Mandates: US National Institutes of Health
Extracellular vesicles impose quiescence on residual hematopoietic stem cells in the leukemic niche
S Abdelhamed, JT Butler, B Doron, A Halse, E Nemecek, PA Wilmarth, ...
EMBO reports 20 (7), e47546, 2019
Mandates: US National Institutes of Health
Pediatric Hodgkin lymphoma: are we over-scanning our patients?
N Rathore, HM Eissa, JF Margolin, H Liu, MF Wu, T Horton, K Kamdar, ...
Pediatric hematology and oncology 29 (5), 415-423, 2012
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program